Welcome to our dedicated page for Cormedix SEC filings (Ticker: CRMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CorMedix Inc. filings document the regulatory record of a Nasdaq-listed biopharmaceutical company commercializing DefenCath and a broader portfolio of institutional-care specialty pharmaceuticals. Form 8-K reports cover operating results, financial condition, corporate presentations, material-event disclosures, clinical or regulatory updates and business developments following the completed Melinta Therapeutics acquisition.
Proxy statements describe shareholder voting matters, board and governance practices, equity incentive plan proposals, certificate of incorporation matters and preferred-stock voting provisions. Acquisition-related amendments include financial statements of the acquired business and pro forma financial information, while the company’s securities disclosures identify CRMD common stock listed on the Nasdaq Global Market.
CorMedix Inc. Chief Financial Officer Susan Blum filed an initial ownership report on Form 3 in connection with her role as an officer of CorMedix Inc. The filing states that no securities of CorMedix Inc. are beneficially owned, and both the non-derivative and derivative ownership tables show no holdings. The form is filed by a single reporting person in her capacity as Chief Financial Officer.
CorMedix Inc. (CRMD) has filed a Form 144 reporting a proposed sale of 300,000 common shares through Merrill Lynch on 09/03/2025 on the NASDAQ, with an aggregate market value of $4,350,000.00. The filing shows the shares were acquired and are to be paid for on 09/03/2025 under a Stock Plan Activity from the issuer. The company reports 74,648,992 shares outstanding, so the proposed sale represents approximately 0.40% of outstanding common stock. The filer indicates there were no shares sold by the same person in the past three months and includes the standard certification that no material nonpublic information is known by the seller.
CorMedix Inc. filed an 8-K that includes a press release dated September 2, 2025 and is signed by CEO Joseph Todisco. The filing discloses contingent payment obligations tied to potential FDA-approved labeling: $20 million if labeling includes candida, $2.5 million if labeling includes aspergillus, and $2.5 million if labeling includes pneumocystis. Portions of an exhibit have been omitted pursuant to Item 601(b)(2)(ii) of Regulation S-K. The document also contains contact information and standard exchange-act checkbox items, but the text provided here appears truncated and does not include the full press release or additional financial detail.
CorMedix Inc. completed its previously announced private placement of $150,000,000 aggregate principal amount of convertible senior notes due 2030, issued in reliance on Section 4(a)(2) of the Securities Act. The company entered into an indenture with U.S. Bank Trust Company, National Association, as trustee, and the indenture and form of note are filed as Exhibits 4.1 and 4.2.
The notes bear a stated rate reflected in the form of the notes as 4.00% and have an initial conversion rate of 74.2515 shares per $1,000 principal amount (approximately $13.47 per share implied by that rate). The notes and any common stock issuable upon conversion have not been registered under the Securities Act and may not be offered or sold in the United States absent registration or an applicable exemption.
On 8 Aug 2025, individual investor Shaibatalhamd Aymen Abdalkader filed Amendment No. 2 to Schedule 13G, revealing a passive ownership position in CorMedix Inc. (CRMD).
- Shares owned: 4,645,630 common shares.
- Ownership percentage: 6.22 % of CorMedix’s outstanding stock, exceeding the 5 % disclosure threshold.
- Control rights: Sole voting and sole dispositive power over all reported shares; no shared control.
- Intent: Filer certifies the stake is not intended to influence or change control of the issuer.
No purchase prices, transaction dates, or financing details were disclosed. While the filing signals meaningful individual interest in CRMD, it conveys a passive stance and does not, by itself, indicate imminent strategic or governance changes.
CorMedix (CRMD) delivered its first profitable quarter since commercial launch of DefenCath. Q2-25 net sales surged to $39.7 m from $0.8 m a year ago, lifting H1 revenue to $78.8 m. Gross margin was 95% and operating income reached $19.5 m versus a $15.3 m loss in Q2-24; H1 operating income was $39.7 m. Net income came in at $19.8 m (-dil. EPS $0.28) for the quarter and $40.5 m for six months, despite a $2.0 m negative adjustment to Medicaid rebate estimates.
Liquidity strengthened sharply: cash and equivalents rose to $159.3 m and short-term investments to $31.4 m, driven by a $82.4 m June equity offering, $6.8 m ATM sales and $1.5 m option exercises. Stockholders’ equity climbed to $220.6 m from $84.7 m year-end.
Customer concentration remains high (Customer A 59% of Q2 sales; 45% of receivables). Gross-to-net deductions totalled $41.3 m YTD (52% of gross sales).
Strategic moves: • August 2025 agreement to acquire Melinta Therapeutics for $260 m cash + $40 m shares; closing expected Sept-25. • Parallel $150 m 4.0% senior convertible notes due 2030 to partly fund the deal. • OBBBA tax law change (July-25) expected to lower future cash taxes.
Balance sheet shows no long-term debt yet; pro-forma leverage will rise post-note issuance. Litigation (securities & derivative) continues, discovery stage.
CorMedix (CRMD) delivered its first profitable quarter since commercial launch of DefenCath. Q2-25 net sales surged to $39.7 m from $0.8 m a year ago, lifting H1 revenue to $78.8 m. Gross margin was 95% and operating income reached $19.5 m versus a $15.3 m loss in Q2-24; H1 operating income was $39.7 m. Net income came in at $19.8 m (-dil. EPS $0.28) for the quarter and $40.5 m for six months, despite a $2.0 m negative adjustment to Medicaid rebate estimates.
Liquidity strengthened sharply: cash and equivalents rose to $159.3 m and short-term investments to $31.4 m, driven by a $82.4 m June equity offering, $6.8 m ATM sales and $1.5 m option exercises. Stockholders’ equity climbed to $220.6 m from $84.7 m year-end.
Customer concentration remains high (Customer A 59% of Q2 sales; 45% of receivables). Gross-to-net deductions totalled $41.3 m YTD (52% of gross sales).
Strategic moves: • August 2025 agreement to acquire Melinta Therapeutics for $260 m cash + $40 m shares; closing expected Sept-25. • Parallel $150 m 4.0% senior convertible notes due 2030 to partly fund the deal. • OBBBA tax law change (July-25) expected to lower future cash taxes.
Balance sheet shows no long-term debt yet; pro-forma leverage will rise post-note issuance. Litigation (securities & derivative) continues, discovery stage.
CorMedix (CRMD) delivered its first profitable quarter since commercial launch of DefenCath. Q2-25 net sales surged to $39.7 m from $0.8 m a year ago, lifting H1 revenue to $78.8 m. Gross margin was 95% and operating income reached $19.5 m versus a $15.3 m loss in Q2-24; H1 operating income was $39.7 m. Net income came in at $19.8 m (-dil. EPS $0.28) for the quarter and $40.5 m for six months, despite a $2.0 m negative adjustment to Medicaid rebate estimates.
Liquidity strengthened sharply: cash and equivalents rose to $159.3 m and short-term investments to $31.4 m, driven by a $82.4 m June equity offering, $6.8 m ATM sales and $1.5 m option exercises. Stockholders’ equity climbed to $220.6 m from $84.7 m year-end.
Customer concentration remains high (Customer A 59% of Q2 sales; 45% of receivables). Gross-to-net deductions totalled $41.3 m YTD (52% of gross sales).
Strategic moves: • August 2025 agreement to acquire Melinta Therapeutics for $260 m cash + $40 m shares; closing expected Sept-25. • Parallel $150 m 4.0% senior convertible notes due 2030 to partly fund the deal. • OBBBA tax law change (July-25) expected to lower future cash taxes.
Balance sheet shows no long-term debt yet; pro-forma leverage will rise post-note issuance. Litigation (securities & derivative) continues, discovery stage.
CorMedix Inc. (Nasdaq: CRMD) has launched a follow-on equity offering under its shelf registration statement, filing a Rule 424(b)(5) prospectus supplement dated June 26 2025. The company is issuing 6,604,507 shares of common stock, with sole book-runner RBC Capital Markets purchasing the shares at $12.641 per share. This represents a 15.6% discount to the June 25 2025 closing price of $14.97. Gross proceeds to CorMedix are expected to be approximately $83.5 million before offering expenses.
The underwriters have a 30-day option to buy up to an additional 990,676 shares, which, if fully exercised, would increase the total raise to roughly $96 million. Shares are expected to be delivered on or about June 30 2025.
The prospectus highlights numerous risk factors, including: sustained operating losses, reliance on a single commercial product (DefenCath), dependence on third-party reimbursement, significant customer concentration, and the need for future financings that could be dilutive or on unfavorable terms. The document expressly cautions that forward-looking statements are subject to uncertainty and that past information may not reflect current conditions.
Key transactional terms
- Offering size: 6.60 million shares
- Offer price to underwriters: $12.641 per share
- Gross proceeds: ~$83.5 million (excluding option)
- Over-allotment option: 990,676 shares (30 days)
- Expected closing: June 30 2025
No specific use-of-proceeds breakdown is provided in the excerpt; investors are directed to the “Use of Proceeds” section (page S-6) for details. The filing reiterates that neither the SEC nor state regulators have approved or disapproved the securities and that investing involves substantial risk.
CorMedix Inc. (Nasdaq: CRMD) has filed a preliminary prospectus supplement under Rule 424(b)(5) for a common-stock offering of up to US$85 million. The company has not yet disclosed the number of shares or the final offering price, but the last reported market price on 25 June 2025 was $14.97 per share. RBC Capital Markets is the sole book-running manager, and the underwriters hold a 30-day option to purchase additional shares. The shares will be offered on Nasdaq or through negotiated transactions at prevailing or negotiated prices.
The filing forms part of CorMedix’s shelf registration statement dated 22 May 2024. Key sections include Use of Proceeds (S-6), Dilution (S-7) and Underwriting (S-10). Although precise use of proceeds is not specified in this preliminary document, management cites a continued need to finance operations and commercial expansion.
Risk highlights listed on pages S-4 onward emphasise: (i) a history of operating losses and the possibility of never achieving sustained profitability; (ii) heavy reliance on a single approved product, DefenCath®, with concentrated customers and reimbursement uncertainties; (iii) potential dilution and unfavourable terms from future financings; and (iv) regulatory and commercialisation uncertainties for pipeline products.
Investors are advised to review the full prospectus supplement, incorporated documents and forward-looking statements for detailed risk disclosures before committing capital.